Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A
300026.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.97B
Close$
$7.73
137.9% upside
Current Fair Value
137.9% upsideUndervalued by 137.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.97 Billion |
|---|---|
| Enterprise Value | $8.79 Billion |
| Dividend Yield | $0.01 (0.30%) |
| Earnings per Share | $0.01 |
| Beta | 0.03 |
| Outstanding Shares | 3,004,154,837 |
Return
| Return on Equity | 0.21% |
|---|---|
| Return on Assets | 0.17% |
| Return on Invested Capital | 1.16% |
Valuation & Multiples
| P/E Ratio | 790.48 |
|---|---|
| PEG | -2441.04 |
| Price to Sales | 3.25 |
| Price to Book Ratio | 1.63 |
| Enterprise Value to Revenue | 2.03 |
| Enterprise Value to EBIT | 84.24 |
| Enterprise Value to Net Income | 489 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A
4,852 employees
CEO: Wu Jun Lan Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research and development, production, and sale of various pharmaceutical products in China and internationally. The company provides Chinese medicine formula granules, finished drug...